Amarin Corp Plcuk (AMRN) Shares Outstanding (Weighted Average) (2010 - 2026)

Amarin Corp Plcuk (AMRN) reported Shares Outstanding (Weighted Average) of $419.1 million for Q1 2026, up 1.36% year-over-year from $413.4 million in Q1 2025, and up 0.98% quarter-over-quarter from $415.0 million in Q4 2025.

Amarin Corp Plcuk (AMRN) Shares Outstanding (Weighted Average) (2010 - 2026) Analysis & Trends

Amarin Corp Plcuk (AMRN) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $419.1 million in Q1 2026.

  • Shares Outstanding (Weighted Average) for Q1 2026 came in at $419.1 million, up 1.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $419.1 million (up 1.36% YoY), and the FY2025 annual result was $415.0 million, up 0.98% from the prior year.
  • Shares Outstanding (Weighted Average) advanced to $419.1 million in Q1 2026 per AMRN's latest filing, from $415.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $419.1 million in Q1 2026 and troughed at $397.8 million in Q1 2022.
  • A 5-year average of $408.9 million and a median of $410.1 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
  • The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) advanced 2.27% in 2023, then grew 0.67% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $401.2 million in 2022, then climbed by 1.62% to $407.7 million in 2023, then grew by 0.81% to $410.9 million in 2024, then advanced by 0.98% to $415.0 million in 2025, then grew by 0.98% to $419.1 million in 2026.
  • Business Quant data shows AMRN's Shares Outstanding (Weighted Average) at $419.1 million in Q1 2026, $415.0 million in Q4 2025, and $415.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Weighted Avg.) (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 1,818,692.66 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 894.50 Mn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 2.41 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 1.77 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 2.47 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 540.00 Mn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 1.24 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 5.69 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 2.04 Bn
10 Amarin Corp Plcuk 5.84 Bn 5.66 Bn 17.77 Mn 419.05 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 419.05 Mn
Dec 31, 2025 414.98 Mn
Sep 30, 2025 415.53 Mn
Jun 30, 2025 414.48 Mn
Mar 31, 2025 413.42 Mn
Dec 31, 2024 410.94 Mn
Sep 30, 2024 411.15 Mn
Jun 30, 2024 410.57 Mn
Mar 31, 2024 410.15 Mn
Dec 31, 2023 407.66 Mn
Sep 30, 2023 408.42 Mn
Jun 30, 2023 407.02 Mn
Mar 31, 2023 406.18 Mn
Dec 31, 2022 401.16 Mn
Sep 30, 2022 404.61 Mn
Jun 30, 2022 398.00 Mn
Mar 31, 2022 397.81 Mn
Dec 31, 2021 395.99 Mn
Sep 30, 2021 396.62 Mn
Jun 30, 2021 395.27 Mn